Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haemoglobin-based oxygen carriers.

K D Vandegriff1

  • 1Sangart, Inc., 11199 Sorrento Valley Rd, Ste. L, San Diego, CA 92121, USA. kvandegriff@sangart.com

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats.

British journal of pharmacology·2008
Same author

The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers.

Biophysical chemistry·2001
Same author

Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model.

Journal of applied physiology (Bethesda, Md. : 1985)·1998
Same author

Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide.

The Journal of biological chemistry·1998
Same author

Hemoglobin-oxygen equilibrium curves measured during enzymatic oxygen consumption.

Analytical biochemistry·1998
Same author

Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated.

Biophysical chemistry·1998

Haemoglobin-based oxygen carriers face challenges in clinical trials, with some discontinued due to adverse events. Ongoing research focuses on improving efficacy and safety for blood replacement therapies.

Area of Science:

  • Biotechnology
  • Biomaterials Science
  • Hematology

Background:

  • High demand for blood replacement therapies due to transfusion risks and blood shortages.
  • Cell-free hemoglobin requires modification for circulation retention in blood replacement products.
  • Development of hemoglobin-based oxygen carriers (HBOCs) addresses critical medical needs.

Purpose of the Study:

  • To review the development and clinical trial status of HBOCs.
  • To identify challenges and adverse events associated with different HBOC classes.
  • To highlight the need for improved understanding of HBOCs' efficacy and safety.

Main Methods:

  • Review of three classes of HBOCs: intramolecular cross-linked, intermolecular polymerised, and surface conjugated.
  • Analysis of clinical trial outcomes, including Phase III results.

Related Experiment Videos

  • Examination of reported adverse events and efficacy data.

    • Main Results:

    • Two cross-linked HBOCs discontinued in Phase III due to adverse events and mortality.
    • Three polymerised HBOCs are in ongoing Phase III trials.
    • Surface-conjugated HBOCs are in preclinical evaluation; cross-linked and polymerised products show safety but struggle with efficacy.
    • Common adverse effect is a haemodynamic response causing increased vascular resistance.

    Conclusions:

    • HBOC development faces significant safety and efficacy hurdles, particularly regarding haemodynamic responses.
    • Further research into HBOCs' mechanisms of action is crucial for defining their clinical utility.
    • New HBOC designs aim to optimize blood flow, tissue perfusion, and oxygenation.